Femasys Inc. (FEMY)
NASDAQ: FEMY · IEX Real-Time Price · USD
1.270
-0.060 (-4.51%)
At close: Apr 26, 2024, 4:00 PM
1.260
-0.010 (-0.79%)
After-hours: Apr 26, 2024, 7:52 PM EDT
Femasys Revenue
In the year 2023, Femasys had annual revenue of $1.07M, a decrease of -11.13%. Revenue in the quarter ending December 31, 2023 was $213.11K, a -9.02% decrease year-over-year.
Revenue (ttm)
$1.07M
Revenue Growth
-11.13%
P/S Ratio
26.18
Revenue / Employee
$33,499
Employees
32
Market Cap
28.07M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.07M | -134.25K | -11.13% |
Dec 31, 2022 | 1.21M | 26.53K | 2.25% |
Dec 31, 2021 | 1.18M | 141.77K | 13.66% |
Dec 31, 2020 | 1.04M | 108.85K | 11.72% |
Dec 31, 2019 | 929.06K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CASI Pharmaceuticals | 33.88M |
ImmunoPrecise Antibodies | 17.67M |
Singular Genomics Systems | 2.91M |
NeuroOne Medical Technologies | 2.82M |
Daré Bioscience | 2.81M |
IGC Pharma | 1.22M |
FEMY News
- 8 days ago - Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives - GlobeNewsWire
- 4 weeks ago - Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape - GlobeNewsWire
- 5 weeks ago - Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility - GlobeNewsWire
- 7 weeks ago - Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution - GlobeNewsWire
- 2 months ago - Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF - GlobeNewsWire
- 2 months ago - Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer - GlobeNewsWire
- 3 months ago - Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women - GlobeNewsWire